{"date":"2026-06-03","count":17,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-7871-2026-06-03-2131-4ofddj","company_id":"7871","company":"安立璽榮-KY","market":"興櫃","industry":"生技醫療","date":"2026-06-03","time":"21:31:59","subject":"代子公司安立璽榮生醫股份有限公司公告用於治療阿茲海默症（Alzheimer’s Disease）之新藥EI-1071第二期人體臨床試驗期中數據。","clause":"第44款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：安立璽榮-KY（7871），2026-06-03 21:31，「代子公司安立璽榮生醫股份有限公司公告用於治療阿茲海默症（Alzheimer’s Disease）之新藥EI-1071第二」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1271-2026-06-03-1854-qaf3j2","company_id":"1271","company":"晨暉生技","market":"興櫃","industry":"生技醫療","date":"2026-06-03","time":"18:54:48","subject":"公告本公司115年股東常會通過解除新任董事及其代表人競業行為之限制案","clause":"第22款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：晨暉生技（1271），2026-06-03 18:54，「公告本公司115年股東常會通過解除新任董事及其代表人競業行為之限制案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1271-2026-06-03-1854-za3byx","company_id":"1271","company":"晨暉生技","market":"興櫃","industry":"生技醫療","date":"2026-06-03","time":"18:54:13","subject":"公告本公司第四屆審計委員會委員名單","clause":"第6款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：晨暉生技（1271），2026-06-03 18:54，「公告本公司第四屆審計委員會委員名單」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1271-2026-06-03-1853-zhkfod","company_id":"1271","company":"晨暉生技","market":"興櫃","industry":"生技醫療","date":"2026-06-03","time":"18:53:45","subject":"公告本公司115年股東常會全面改選董事當選名單","clause":"第6款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：晨暉生技（1271），2026-06-03 18:53，「公告本公司115年股東常會全面改選董事當選名單」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1271-2026-06-03-1853-1jb8ii5","company_id":"1271","company":"晨暉生技","market":"興櫃","industry":"生技醫療","date":"2026-06-03","time":"18:53:07","subject":"公告本公司115年股東常會重要決議事項","clause":"第15款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：晨暉生技（1271），2026-06-03 18:53，「公告本公司115年股東常會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4190-2026-06-03-1804-1ym0f8w","company_id":"4190","company":"佐登-KY","market":"上市","industry":"生技醫療","date":"2026-06-03","time":"18:04:16","subject":"代子公司SUCCESS UNITED LIMITED公告股利分派","clause":"第14款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：佐登-KY（4190），2026-06-03 18:04，「代子公司SUCCESS UNITED LIMITED公告股利分派」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4190-2026-06-03-1803-uxa4yv","company_id":"4190","company":"佐登-KY","market":"上市","industry":"生技醫療","date":"2026-06-03","time":"18:03:05","subject":"代子公司佐登妮絲(廣州)美容化妝品有限公司公告股利分派","clause":"第14款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：佐登-KY（4190），2026-06-03 18:03，「代子公司佐登妮絲(廣州)美容化妝品有限公司公告股利分派」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2026-06-03-1712-h201le","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2026-06-03","time":"17:12:34","subject":"本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之3b期長期追蹤臨床試驗CBL-0303申請，今日已完成美國FDA送件","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2026-06-03 17:12，「本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之3b期長期追蹤臨床試驗CBL-0303申請，今日已完成美國FDA送件」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2026-06-03-1702-d4jsal","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2026-06-03","time":"17:02:40","subject":"公告本公司115年第一次現金增資收足股款暨增資基準日","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2026-06-03 17:02，「公告本公司115年第一次現金增資收足股款暨增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6986-2026-06-03-1701-ionnc2","company_id":"6986","company":"和迅","market":"上櫃","industry":"生技醫療","date":"2026-06-03","time":"17:01:35","subject":"本公司研發之異體間質幹細胞新藥HeXell-2020治療老年衰弱症，向台灣衛生福利部食品藥物管理署(TFDA)提出Phase I 人體臨床試驗（IND）申請","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：和迅（6986），2026-06-03 17:01，「本公司研發之異體間質幹細胞新藥HeXell-2020治療老年衰弱症，向台灣衛生福利部食品藥物管理署(TFDA)提出Pha」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6637-2026-06-03-1649-11mi7kj","company_id":"6637","company":"醫影","market":"上櫃","industry":"生技醫療","date":"2026-06-03","time":"16:49:35","subject":"更正115年股東會議事錄部份資訊","clause":"第53款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：醫影（6637），2026-06-03 16:49，「更正115年股東會議事錄部份資訊」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4167-2026-06-03-1640-1whap0z","company_id":"4167","company":"松瑞藥","market":"上櫃","industry":"生技醫療","date":"2026-06-03","time":"16:40:23","subject":"更正本公司115年度中英文股東會議事手冊部分內容","clause":"第53款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：松瑞藥（4167），2026-06-03 16:40，「更正本公司115年度中英文股東會議事手冊部分內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8279-2026-06-03-1630-ziw9j8","company_id":"8279","company":"生展","market":"上櫃","industry":"生技醫療","date":"2026-06-03","time":"16:30:05","subject":"更正-公告本公司115年股東常會全面改選董事當選名單(更正屬三分之一以上董事發生變動)","clause":"第6款","fact_date":"2026-05-27","cite_as":"公開資訊觀測站重大訊息：生展（8279），2026-06-03 16:30，「更正-公告本公司115年股東常會全面改選董事當選名單(更正屬三分之一以上董事發生變動)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6945-2026-06-03-1533-8ujb8r","company_id":"6945","company":"圓祥生技","market":"上櫃","industry":"生技醫療","date":"2026-06-03","time":"15:33:14","subject":"公告本公司股票初次上櫃前現金增資收足股款暨現金增資基準日","clause":"第44款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：圓祥生技（6945），2026-06-03 15:33，「公告本公司股票初次上櫃前現金增資收足股款暨現金增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6945-2026-06-03-1532-1muo30n","company_id":"6945","company":"圓祥生技","market":"上櫃","industry":"生技醫療","date":"2026-06-03","time":"15:32:48","subject":"公告本公司辦理股票初次上櫃過額配售內容","clause":"第44款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：圓祥生技（6945），2026-06-03 15:32，「公告本公司辦理股票初次上櫃過額配售內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3176-2026-06-03-1529-4tqmn5","company_id":"3176","company":"基亞","market":"上櫃","industry":"生技醫療","date":"2026-06-03","time":"15:29:24","subject":"Telomelysin (OBP-301) 提出新適應症臨床試驗申請","clause":"第53款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：基亞（3176），2026-06-03 15:29，「Telomelysin (OBP-301) 提出新適應症臨床試驗申請」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6615-2026-06-03-1521-1jb8ii5","company_id":"6615","company":"慧智","market":"上櫃","industry":"生技醫療","date":"2026-06-03","time":"15:21:10","subject":"公告本公司115年股東常會重要決議事項","clause":"第18款","fact_date":"2026-06-03","cite_as":"公開資訊觀測站重大訊息：慧智（6615），2026-06-03 15:21，「公告本公司115年股東常會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}